| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8, 20q-, Technical Component
Test Code37876
Preferred Specimen
3 - 5 mL whole blood or bone marrow in sodium heparin (green-top), (royal blue-top) or lead-free (tan-top) tube
Minimum Volume
1 mL
Instructions
Specimen viability decreases during transit. Send specimen to testing lab for viability. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: See Instructions
Refrigerated: See Instructions
Frozen: Unacceptable
Refrigerated: See Instructions
Frozen: Unacceptable
Methodology
Fluorescence In Situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
A.M. Sets up 7 days a week.
Report Available
Reports in 5 to 7 days.
Clinical Significance
Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45 50% have at least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hybridization (FISH) panel (-5/5q-, -7/7q-, +8, 20q-). This panel of FISH probes can increase the detection rate of chromosome abnormalities at diagnosis and aid in follow-up testing for clinically significant chromosome abnormalities in MDS. The identification of the specific chromosome regions involved in a patient's disease may play a significant role in treatment decisions as MDS targeted therapies are developed.
